AU2022388507A1 - TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST - Google Patents

TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST Download PDF

Info

Publication number
AU2022388507A1
AU2022388507A1 AU2022388507A AU2022388507A AU2022388507A1 AU 2022388507 A1 AU2022388507 A1 AU 2022388507A1 AU 2022388507 A AU2022388507 A AU 2022388507A AU 2022388507 A AU2022388507 A AU 2022388507A AU 2022388507 A1 AU2022388507 A1 AU 2022388507A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
liver
dose
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022388507A
Other languages
English (en)
Inventor
Jianwei BIAN
D. Barry CRITTENDEN
Qianqian DONG
Matt Duan
Sheng Guo
Feng Jin
Christopher T. Jones
Kevin Klucher
Erin K. QUIRK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terns Pharmaceuticals Inc
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of AU2022388507A1 publication Critical patent/AU2022388507A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
AU2022388507A 2021-11-11 2022-11-11 TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST Pending AU2022388507A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/130083 2021-11-11
CN2021130083 2021-11-11
CN2022097426 2022-06-07
CNPCT/CN2022/097426 2022-06-07
PCT/CN2022/131297 WO2023083288A1 (en) 2021-11-11 2022-11-11 TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST

Publications (1)

Publication Number Publication Date
AU2022388507A1 true AU2022388507A1 (en) 2024-06-20

Family

ID=86335128

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022388507A Pending AU2022388507A1 (en) 2021-11-11 2022-11-11 TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST

Country Status (14)

Country Link
US (1) US20240293416A1 (https=)
EP (1) EP4429666A4 (https=)
JP (1) JP2024544538A (https=)
KR (1) KR20240101642A (https=)
CN (1) CN118871113A (https=)
AU (1) AU2022388507A1 (https=)
CA (1) CA3238108A1 (https=)
CL (1) CL2024001399A1 (https=)
CO (1) CO2024007225A2 (https=)
IL (1) IL312637A (https=)
MX (1) MX2024005647A (https=)
PE (1) PE20241327A1 (https=)
TW (1) TW202332447A (https=)
WO (1) WO2023083288A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
WO2025245216A1 (en) * 2024-05-22 2025-11-27 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-beta agonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018075650A1 (en) * 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a thr-beta agonist
AR115666A1 (es) * 2018-07-02 2021-02-10 Madrigal Pharmaceuticals Inc Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo
CN111320609A (zh) * 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020228577A1 (zh) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
TW202128668A (zh) * 2019-12-16 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 并環類衍生物、其製備方法及其在醫藥上的應用
US20210379043A1 (en) * 2020-05-13 2021-12-09 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法

Also Published As

Publication number Publication date
TW202332447A (zh) 2023-08-16
WO2023083288A1 (en) 2023-05-19
KR20240101642A (ko) 2024-07-02
CN118871113A (zh) 2024-10-29
CL2024001399A1 (es) 2024-11-08
EP4429666A1 (en) 2024-09-18
CA3238108A1 (en) 2023-05-19
US20240293416A1 (en) 2024-09-05
CO2024007225A2 (es) 2024-10-31
EP4429666A4 (en) 2025-12-24
JP2024544538A (ja) 2024-12-03
IL312637A (en) 2024-07-01
PE20241327A1 (es) 2024-06-26
MX2024005647A (es) 2024-05-24

Similar Documents

Publication Publication Date Title
WO2023083288A1 (en) TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST
US20230241071A1 (en) Combination treatment of liver disorders
TWI663975B (zh) 治療肝臟疾病之方法
JP7053478B2 (ja) Ｆｘｒアゴニストを使用するための方法
TW201932109A (zh) 治療肝臟疾病之方法
TW202207928A (zh) 肝病之組合治療
TW201900167A (zh) 治療肝疾病之方法
EP3908279B1 (en) Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
JP2001513558A (ja) アルツハイマー病を治療するためにファンキノンを使用する方法
KR101057485B1 (ko) 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
US20250120981A1 (en) Mrtx1133 pharmaceutical compositions
US11590108B2 (en) Pharmaceutical compositions for combination therapy
US12564600B2 (en) System for enhancing therapeutic compliance of the anti-cancer compound E7766
KR20230087535A (ko) 간 지방증을 역전시키는 방법
CA2637000A1 (en) Methods and compositions for treating prostate cancer, benign prostatic hypertrophy, polycystic ovary syndrome and other conditions
HK40118289A (zh) 使用THR-β激动剂的肝脏病症的治疗
CN115605198B (zh) 脂肪性肝病的治疗药
JP7430916B2 (ja) 心不全の病態の評価のための方法、バイオマーカー、候補化合物の評価方法、医薬用組成物及び心不全の治療剤
RU2857392C2 (ru) Способы лечения синдрома семейной хиломикронемии
RU2849641C1 (ru) Терапевтическое средство против жировой болезни печени
RU2820595C2 (ru) Система для повышения степени соблюдения терапевтической схемы с противораковым соединением e7766
HK40113179A (zh) 以回肠胆汁酸转运蛋白(ibat)抑制剂治疗以增加无事件存活期(efs)
HK40053265A (en) Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
HK40053265B (en) Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
BR112020006085B1 (pt) Métodos para inibir a conversão de colina em trimetilamina (tma)